The presence of metabolic syndrome is independently associated with elevated serum CD40 ligand and disease severity in patients with symptomatic coronary artery disease

Metabolism: Clinical and Experimental

Volumn 55, Issue 8, 2006, Pages 1029-1034

  Lee, Wen Lieng ^a,b   Lee, Wen Jane ^a   Chen, Ying Tsung ^a,c   Liu, Tsun Jui ^a,b   Liang, Kae Woei ^a,b   Ting, Chih Tai ^a,b   Huey Herng Sheu, Wayne ^a,b,c  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD40 LIGAND; CELL ADHESION MOLECULE; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN;

AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; EDUCATION PROGRAM; FEMALE; HUMAN; INCIDENCE; LIGAND BINDING; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORTALITY; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL;

AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CD40 LIGAND; CELL ADHESION MOLECULES; CHEMOKINE CCL2; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CORONARY RESTENOSIS; CYTOKINES; FEMALE; HUMANS; INSULIN; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED;

EID: 33745727432     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2006.03.013     Document Type: Article

References (37)

1. Schonbeck U. Libby P CD40 signaling and plaque instability. Circ Res 89 (2001) 1092-1103
2. Garlichs C.D., John S., Schmeisser A., et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 104 (2001) 2395-2400
3. Aukrust P., Muller F., Ueland T., et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100 (1999) 614-620
4. Heeschen C., Dimmeler S., Hamm C.W., et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348 (2003) 1104-1111
5. Varo N., de Lemos J.A., Libby P., et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 108 (2003) 1049-1052
6. Cipollone F., Ferri C., Desideri G., et al. Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. Circulation 108 (2003) 2776-2782
7. de Lemos J.A., Morrow D.A., Sabatine M.S., et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 107 (2003) 690-695
8. Huo Y., and Ley K. Adhesion molecules and atherogenesis. Acta Physiol Scand 173 (2001) 35-43
9. Lee W.L., Sheu W.H., Liu T.J., et al. The short-/intermediate-term changes in novel vascular inflammatory markers after angioplasty plus stenting in patients with symptomatic advanced systemic arterial diseases. Atherosclerosis 176 (2004) 125-132
10. Hope S.A., and Meredith I.T. Cellular adhesion molecules and cardiovascular disease. Part I. Their expression and role in atherogenesis. Intern Med J 33 (2003) 380-386
11. Szmitko P.E., Wang C.H., Weisel R.D., et al. New markers of inflammation and endothelial cell activation: Part I. Circulation 108 (2003) 1917-1923
12. Reilly M.P., and Rader D.J. The metabolic syndrome: more than the sum of its parts?. Circulation 108 (2003) 1546-1551
13. Third Report of the. National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
14. Alexander C.M., Landsman P.B., Teutsch S.M., et al. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52 (2003) 1210-1214
15. Wong N.D., Sciammarella M.G., Polk D., et al. The metabolic syndrome, diabetes, and subclinical atherosclerosis assessed by coronary calcium. J Am Coll Cardiol 41 (2003) 1547-1553
16. Wilson P.W., D'Agostino R.B., Parise H., et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 112 (2005) 3066-3072
17. Malik S., Wong N.D., Franklin S.S., et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110 (2004) 1245-1250
18. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
19. Rutter M.K., Meigs J.B., Sullivan L.M., et al. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110 (2004) 380-385
20. Festa A., D'Agostino Jr. R., Howard G., et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102 (2000) 42-47
21. Solymoss B.C., Bourassa M.G., Campeau L., et al. Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. Am J Cardiol 93 (2004) 159-164
22. Birhanyilmaz M., Guray U., Guray Y., et al. Metabolic syndrome is associated with extension of coronary artery disease in patients with non-ST segment elevation acute coronary syndromes. Coron Artery Dis 16 (2005) 287-292
23. Gensini G.G. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 51 (1983) 606
24. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
25. Reilly M.P., Wolfe M.L., Rhodes T., et al. Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation 110 (2004) 803-809
26. Gu D., Reynolds K., Wu X., et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 365 (2005) 1398-1405
27. Marroquin O.C., Kip K.E., Kelley D.E., et al. Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the Women's Ischemia Syndrome Evaluation. Circulation 109 (2004) 714-721
28. Haffner S., and Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation 108 (2003) 1541-1545
29. Wannamethee S.G., Lowe G.D., Shaper A.G., et al. The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older non-diabetic men. Atherosclerosis 181 (2005) 101-108
30. Lee W.Y., Park J.S., Noh S.Y., et al. C-reactive protein concentrations are related to insulin resistance and metabolic syndrome as defined by the ATP III report. Int J Cardiol 97 (2004) 101-106
31. Ridker P.M., Buring J.E., Cook N.R., et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 107 (2003) 391-397
32. Yudkin J.S., Juhan-Vague I., Hawe E., et al. Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. Metabolism 53 (2004) 852-857
33. Andre P., Nannizzi-Alaimo L., Prasad S.K., et al. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 106 (2002) 896-899
34. Mach F., Schonbeck U., Sukhova G.K., et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U S A 94 (1997) 1931-1936
35. Karmann K., Hughes C.C., Schechner J., et al. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci U S A 92 (1995) 4342-4346
36. Bonora E., Kiechl S., Willeit J., et al. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. Diabetes Care 26 (2003) 1251-1257
37. Olijhoek J.K., van der G.Y., Banga J.D., et al. The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 25 (2004) 342-348